1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: M.V.I Adult Multi-Vitamin Infusion (Hospira, Inc.)

Trade Name: Not established
Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product

Details of the Supplier of the Safety Data Sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Hospira UK Limited
Horizon
Honey Lane
Hurley
Maidenhead, SL6 6RJ
United Kingdom

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300

International CHEMTREC (24 hours): +1-703-527-3887

Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification: Not classified as hazardous

Label Elements

Signal Word: Not Classified
Hazard Statements: Not classified in accordance with international standards for workplace safety.

Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous
3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ascorbic acid (Vitamin C)</td>
<td>50-81-7</td>
<td>200-066-2</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>Ergocalciferol (Vitamin D)</td>
<td>50-14-6</td>
<td>200-014-9</td>
<td>Acute Tox. 3 (H301) STOT RE 1 (H372) Acute Tox. 2 (H330)</td>
<td>&lt;0.1</td>
</tr>
<tr>
<td>Folic Acid</td>
<td>59-30-3</td>
<td>200-419-0</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>Niacinamide</td>
<td>98-92-0</td>
<td>202-713-4</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>Phytonadione (Vit.K)</td>
<td>84-80-0</td>
<td>201-564-2</td>
<td>Not Listed</td>
<td>&lt;1.0</td>
</tr>
<tr>
<td>Propylene glycol</td>
<td>57-55-6</td>
<td>200-338-0</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>Riboflavin (Vitamin B2)</td>
<td>83-88-5</td>
<td>201-507-1</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>Biotin</td>
<td>58-85-5</td>
<td>200-399-3</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>Cyanocobalamin (Vitamin B12)</td>
<td>68-19-9</td>
<td>200-680-0</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>Dexpanthenol</td>
<td>81-13-0</td>
<td>201-327-3</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>Gentisic Acid Ethanolamide</td>
<td>61969-53-7</td>
<td>263-358-9</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>Polysorbate 80</td>
<td>9005-65-6</td>
<td>500-019-9</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>Pyridoxine Hydrochloride (Vitamin B6)</td>
<td>58-56-0</td>
<td>200-386-2</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>Sodium citrate, dihydrate</td>
<td>6132-04-3</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>Sodium Phosphate Monobasic, Monohydrate</td>
<td>10049-21-5</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>Thiamine</td>
<td>67-03-8</td>
<td>200-641-8</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>Vitamin A</td>
<td>68-26-8</td>
<td>200-683-7</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>Vitamin E acetate</td>
<td>7695-91-2</td>
<td>231-710-0</td>
<td>Not Listed</td>
<td></td>
</tr>
</tbody>
</table>

**Additional Information:**
* Proprietary Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

**For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16**

4. FIRST AID MEASURES

**Description of First Aid Measures**

**Eye Contact:**
Flush eye(s) immediately with plenty of water. If irritation occurs or persists, get medical attention.

**Skin Contact:**
Wash skin with soap and plenty of water. Remove contaminated clothing and shoes. Wash clothing and thoroughly clean shoes before reuse. If irritation occurs or persists, get medical attention.

**Ingestion:**
Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:**
Move to fresh air. If discomfort persists, get medical attention.

**Most Important Symptoms and Effects, Both Acute and Delayed Symptoms and Effects of Exposure:**
For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture
- **Hazardous Combustion Products**: Formation of toxic gases is possible during heating or fire.
- **Fire / Explosion Hazards**: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters
During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up
- **Measures for Cleaning / Collecting**: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.
- **Additional Consideration for Large Spills**: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Cleanup operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling
Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities
- **Storage Conditions**: Handle and store per label and other instructions to maintain product integrity.

Specific end use(s):
Pharmaceutical product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters
Refer to available public information for specific member state Occupational Exposure Limits.

Niacinamide
- **Latvia OEL - TWA**: 1 mg/m³

PZ03609
### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

<table>
<thead>
<tr>
<th>Substance</th>
<th>Pfizer Occupational Exposure Band (OEB):</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lithuania OEL - TWA</td>
<td>1 mg/m³</td>
</tr>
<tr>
<td>Folic Acid</td>
<td>OEB 3 (control exposure to the range of 10ug/m³ to &lt; 100ug/m³)</td>
</tr>
<tr>
<td>Phytonadione (Vit.K)</td>
<td>OEB 3 (control exposure to the range of 10ug/m³ to &lt; 100ug/m³)</td>
</tr>
</tbody>
</table>

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

**Engineering Controls:** Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

**Personal Protective Equipment:** Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

**Hands:** Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

**Eyes:** Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

**Skin:** Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

**Respiratory protection:** Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)
### 9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Physical State:</th>
<th>Liquid</th>
<th>Color:</th>
<th>Clear to Light straw</th>
</tr>
</thead>
<tbody>
<tr>
<td>Odor:</td>
<td>No data available</td>
<td>Odor Threshold:</td>
<td>No data available</td>
</tr>
<tr>
<td>Molecular Formula:</td>
<td>Mixture</td>
<td>Molecular Weight:</td>
<td>Mixture</td>
</tr>
<tr>
<td>Solvent Solubility:</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Water Solubility:</td>
<td>Soluble</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Solubility:</td>
<td>Slightly Soluble: methanol</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pH:</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melting/Freezing Point (°C):</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Boiling Point (°C):</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Partition Coefficient: (Method, pH, Endpoint, Value)</td>
<td>No data available</td>
<td>No data available</td>
<td></td>
</tr>
<tr>
<td>Phytonadione (Vit.K)</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Biotin</strong></td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cyanocobalamin (Vitamin B12)</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dexamethasone</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gentisic Acid Ethanolamide</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polysorbate 80</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pyridoxine Hydrochloride (Vitamin B6)</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium Phosphate Monobasic, Monohydrate</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium citrate, dihydrate</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thiamine</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin A</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin E acetate</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ergocalciferol (Vitamin D)</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ascorbic acid (Vitamin C)</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Folic Acid</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Niacinamide</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Riboflavin (Vitamin B2)</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Propylene glycol</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decomposition Temperature (°C):</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Evaporation Rate (Gram/s):</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vapor Pressure (kPa):</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET

Material Name: M.V.I Adult Multi-Vitamin Infusion (Hospira, Inc.)
Revision date: 30-Nov-2018

Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available
Flammability:
  Autoignition Temperature (Solid) (°C): No data available
  Flammability (Solids): No data available
  Flash Point (Liquid) (°C): No data available
  Upper Explosive Limits (Liquid) (% by Vol.): No data available
  Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
  Oxidizing Properties: No data available
  Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
  Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects
General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Polysorbate 80
  Rat Intravenous LD50 1790 mg/kg
  Mouse Oral LD50 25 g/kg

Vitamin A
  Rat Oral LD50 2 g/kg

Vitamin E acetate
  Rat Oral LD50 > 16,000 mg/kg
  Rat Dermal LD50 > 3000 mg/kg

Ascorbic acid (Vitamin C)
  Rat Oral LD50 11.9 g/kg

Folic Acid
  Mouse Oral LD50 10 g/kg

Propylene glycol
  Rat Oral LD50 22,000 mg/kg
  Mouse Oral LD50 24,900 mg/kg
  Rabbit Dermal LD50 20,800 mg/kg
11. TOXICOLOGICAL INFORMATION

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Propylene glycol
Skin Irritation Rabbit Mild
Eye Irritation Rabbit Mild

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below

Phytonadione (Vit.K)
IARC: Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.
15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Ascorbic acid (Vitamin C)
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- REACH - Annex IV - Exemptions from the obligations of Register:
  - EU EINECS/ELINCS List: 200-066-2

Biotin
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: 200-399-3

Cyanocobalamin (Vitamin B12)
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: 200-680-0

Dexpanthenol
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: 201-327-3

Ergocalciferol (Vitamin D)
- CERCLA/SARA 313 Emission reporting: Not Listed
- CERCLA/SARA - Section 302 Extremely Hazardous TPQs: 1000 lb
- CERCLA/SARA - Section 302 Extremely Hazardous Substances EPCRA RQs: 10000 lb
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- Standard for the Uniform Scheduling for Drugs and Poisons:
  - Schedule 6
- EU EINECS/ELINCS List: 200-014-9
15. REGULATORY INFORMATION

Folic Acid

| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65           | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present |
| Australia (AICS)                   | Present |
| Standard for the Uniform Scheduling | Schedule 2 |
| for Drugs and Poisons:             | Schedule 4 |
| EU EINECS/ELINCS List              | 200-419-0 |

Gentisic Acid Ethanolamide

| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65           | Not Listed |
| EU EINECS/ELINCS List               | 263-358-9 |

Niacinamide

| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65           | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present |
| Australia (AICS)                   | Present |
| EU EINECS/ELINCS List              | 202-713-4 |

Phytonadione (Vit.K)

| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65           | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present |
| Australia (AICS)                   | Present |
| EU EINECS/ELINCS List              | 201-564-2 |

Polysorbate 80

| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65           | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present |
| Australia (AICS)                   | Present |
| EU EINECS/ELINCS List              | 500-019-9 |

Propylene glycol

| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65           | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present |
| Australia (AICS)                   | Present |
| EU EINECS/ELINCS List              | 200-338-0 |

Pyridoxine Hydrochloride (Vitamin B6)

| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65           | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present |
| Australia (AICS)                   | Present |
| EU EINECS/ELINCS List              | 200-386-2 |

Riboflavin (Vitamin B2)
15. REGULATORY INFORMATION

**Sodium citrate, dihydrate**
- **CERCLA/SARA 313 Emission reporting**: Not Listed
- **California Proposition 65**: Not Listed
- **Australia (AICS)**: Present
- **EU EINECS/ELINCS List**: Not Listed

**Sodium Phosphate Monobasic, Monohydrate**
- **CERCLA/SARA 313 Emission reporting**: Not Listed
- **California Proposition 65**: Not Listed
- **Australia (AICS)**: Present
- **EU EINECS/ELINCS List**: Not Listed

**Thiamine**
- **CERCLA/SARA 313 Emission reporting**: Not Listed
- **California Proposition 65**: Not Listed
- **Inventory - United States TSCA - Sect. 8(b)**: Present
- **Australia (AICS)**: Present
- **EU EINECS/ELINCS List**: 200-641-8

**Vitamin A**
- **CERCLA/SARA 313 Emission reporting**: Not Listed
- **California Proposition 65**: Not Listed
- **Inventory - United States TSCA - Sect. 8(b)**: Present
- **Australia (AICS)**: Present
- **Standard for the Uniform Scheduling for Drugs and Poisons**: Schedule 4
- **EU EINECS/ELINCS List**: 200-683-7

**Vitamin E acetate**
- **CERCLA/SARA 313 Emission reporting**: Not Listed
- **California Proposition 65**: Not Listed
- **Inventory - United States TSCA - Sect. 8(b)**: Present
- **Australia (AICS)**: Present
- **EU EINECS/ELINCS List**: 231-710-0

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3
SAFETY DATA SHEET

Material Name: M.V.I Adult Multi-Vitamin Infusion (Hospira, Inc.)
Revision date: 30-Nov-2018

Acute toxicity, oral-Cat.3; H301 - Toxic if swallowed
Acute toxicity, inhalation-Cat.3; H330 - Fatal if inhaled
Specific target organ toxicity, repeated exposure-Cat.1; H372 - Causes damage to organs through prolonged or repeated exposure

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.
Reasons for Revision: New data sheet.
Revision date: 30-Nov-2018

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet